About Bronchiolitis Obliterans Syndrome
Bronchiolitis obliterans syndrome is a progressive fibro-obliterative disorder of the small airways that represents the major form of chronic lung allograft dysfunction following lung or haematopoietic stem cell transplantation. It is characterised by concentric fibrosis of bronchiolar walls leading to airflow obstruction that is not fully reversible with bronchodilators. Non-transplant causes include toxic fume inhalation, connective tissue disease, and autoimmune conditions, but the post-transplant form is most prevalent and studied.
Common Clinical Features
Clinical Trial Eligibility Tips
What to know before applying to Bronchiolitis Obliterans Syndrome trials.
BOS is staged by percentage decline in FEV1 from post-transplant baseline (BOS 0-3); confirm your current BOS stage as trials often specify eligible stages.
Active acute rejection or concurrent infection usually disqualifies patients; ensure these are resolved and documented before applying.
Time since transplant and immunosuppression regimen are common eligibility variables; have your transplant centre provide a detailed medication history.
Patient Resources
Find recruiting Bronchiolitis Obliterans Syndrome trials
Search 500,000+ studies from ClinicalTrials.gov, filtered for Bronchiolitis Obliterans Syndrome. Updated daily.